全文获取类型
收费全文 | 7659篇 |
免费 | 528篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 313篇 |
妇产科学 | 122篇 |
基础医学 | 933篇 |
口腔科学 | 89篇 |
临床医学 | 730篇 |
内科学 | 1622篇 |
皮肤病学 | 103篇 |
神经病学 | 800篇 |
特种医学 | 348篇 |
外科学 | 1208篇 |
综合类 | 37篇 |
预防医学 | 534篇 |
眼科学 | 118篇 |
药学 | 569篇 |
中国医学 | 14篇 |
肿瘤学 | 653篇 |
出版年
2024年 | 14篇 |
2023年 | 95篇 |
2022年 | 121篇 |
2021年 | 200篇 |
2020年 | 168篇 |
2019年 | 211篇 |
2018年 | 259篇 |
2017年 | 232篇 |
2016年 | 215篇 |
2015年 | 257篇 |
2014年 | 328篇 |
2013年 | 424篇 |
2012年 | 604篇 |
2011年 | 619篇 |
2010年 | 317篇 |
2009年 | 287篇 |
2008年 | 484篇 |
2007年 | 501篇 |
2006年 | 506篇 |
2005年 | 413篇 |
2004年 | 408篇 |
2003年 | 370篇 |
2002年 | 369篇 |
2001年 | 53篇 |
2000年 | 38篇 |
1999年 | 60篇 |
1998年 | 70篇 |
1997年 | 58篇 |
1996年 | 57篇 |
1995年 | 52篇 |
1994年 | 40篇 |
1993年 | 45篇 |
1992年 | 28篇 |
1991年 | 24篇 |
1990年 | 20篇 |
1989年 | 24篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 19篇 |
1984年 | 13篇 |
1983年 | 31篇 |
1982年 | 19篇 |
1981年 | 21篇 |
1980年 | 11篇 |
1979年 | 12篇 |
1978年 | 8篇 |
1977年 | 7篇 |
1975年 | 10篇 |
1967年 | 7篇 |
排序方式: 共有8238条查询结果,搜索用时 15 毫秒
61.
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. 总被引:12,自引:0,他引:12
Eleftherios P Diamandis Andreas Scorilas Stefano Fracchioli Marleen Van Gramberen Henk De Bruijn Alfthan Henrik Antoninus Soosaipillai Linda Grass George M Yousef Ulf-Hakan Stenman Marco Massobrio Ate G J Van Der Zee Ignace Vergote Dionyssios Katsaros 《Journal of clinical oncology》2003,21(6):1035-1043
PURPOSE: The discovery of new ovarian cancer biomarkers that are suitable for early disease diagnosis and prognosis may ultimately lead to improved patient management and outcomes. PATIENTS AND METHODS: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. We then calculated the diagnostic sensitivity and specificity of this test and examined the association of serum hK6 concentration with various clinicopathologic variables and patient survival. RESULTS: Serum hK6 concentration between normal and benign disease patients was not different (mean, 2.9 and 3.1 micro g/L, respectively). However, hK6 in presurgical serum of ovarian cancer patients was highly elevated (mean, 6.8 micro g/L; P <.001). Serum hK6 decreased after surgery (to a mean of 3.9 micro g/L) in 68% of patients. The diagnostic sensitivity of serum hK6 at 90% and 95% specificity is 52% and 47%, respectively, in the whole patient population. For early stage disease (stage I or II), sensitivity is approximately 21% to 26%. When combined with CA-125, at 90% specificity, sensitivity increases to 72% (for all patients) and to 42% in stage I or II disease. Serum hK6 concentration correlates moderately with CA-125 and is higher in patients with late-stage, higher-grade disease and in patients with serous histotype. Preoperative serum hK6 concentration is a powerful predictor of disease-free and overall survival in both univariate and multivariate analyses. CONCLUSIONS: Serum hK6 concentration seems to be a new biomarker for ovarian carcinoma and may have value for disease diagnosis and prognosis. 相似文献
62.
63.
64.
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. 总被引:7,自引:0,他引:7
Freddie Bray Anja H Loos Peter McCarron Elizabete Weiderpass Mark Arbyn Henrik M?ller Matti Hakama D Max Parkin 《Cancer epidemiology, biomarkers & prevention》2005,14(3):677-686
Despite there being sufficient evidence for the effectiveness of screening by cytology in preventing cancer of the cervix uteri, screening policies vary widely among European countries, and incidence is increasing in younger women. This study analyzes trends in squamous cell carcinoma (SCC) of the cervix uteri in 13 European countries to evaluate effectiveness of screening against a background of changing risk. Age-period-cohort models were fitted and period and cohort effects were estimated; these were considered as primarily indicative of screening interventions and changing etiology, respectively. A unique set of estimates was derived by fixing age slopes to one of several plausible age curves under the assumption that the relation between age and cervical cancer incidence is biologically determined. There were period-specific declines in cervical SCC in several countries, with the largest decreases seen in northern Europe. A pattern emerged across Europe of escalating risk in successive generations born after 1930. In the western European countries, a decrease followed by a stabilization of risk by cohort was accompanied by period-specific declines. In southern Europe, stable period, but increasing cohort trends, were observed. Substantial changes have occurred in cervical SCC incidence in Europe and well-organized screening programs have been highly effective in reducing the incidence of cervical SCC. Screening and changing sexual mores largely explain the changing period- and cohort-specific patterns, respectively. The increasing risk in recent cohorts is of obvious concern particularly in countries where no screening programs are in place. Further investigation of the effectiveness of opportunistic screening is warranted as is the observation of differing risk patterns in young cohorts in countries with relatively similar societal structures. 相似文献
65.
Lise Borgwardt Liselotte H?jgaard Henrik Carstensen Henning Laursen Markus Nowak Carsten Thomsen Kjeld Schmiegelow 《Journal of clinical oncology》2005,23(13):3030-3037
PURPOSE Positron emission tomography (PET) has been used in grading of CNS tumors in adults, whereas studies of children have been limited. PATIENTS AND METHODS Nineteen boys and 19 girls (median age, 8 years) with primary CNS tumors were studied prospectively by fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) PET with (n = 16) or without (n = 22) H(2)(15)O-PET before therapy. Image processing included coregistration to magnetic resonance imaging (MRI) in all patients. The FDG uptake in tumors was semiquantitatively calculated by a region-of-interest-based tumor hotspot/brain index. Eight tumors without histologic confirmation were classified as WHO grade 1 based on location, MRI, and clinical course (22 to 42 months). Results Four grade 4 tumors had a mean index of 4.27 +/- 0.5, four grade 3 tumors had a mean index of 2.47 +/- 1.07, 10 grade 2 tumors had a mean index of 1.34 +/- 0.73, and eight of 12 grade 1 tumors had a mean index of -0.31 +/- 0.59. Eight patients with no histologic confirmation had a mean index of 1.04. For these 34 tumors, FDG uptake was positively correlated with malignancy grading (n = 34; r = 0.72; P < .01), as for the 26 histologically classified tumors (n = 26; r = 0.89; P < .01). The choroid plexus papilloma (n = 1) and the pilocytic astrocytomas (n = 3) had a mean index of 3.26 (n = 38; r = 0.57; P < .01). H(2)(15)O-uptake showed no correlation with malignancy. Digitally performed PET/MRI coregistration increased information on tumor characterization in 90% of cases. CONCLUSION FDG PET of the brain with MRI coregistration can be used to obtain a more specific diagnosis with respect to malignancy grading. Improved PET/MRI imaging of the benign hypermetabolic tumors is needed to optimize clinical use. 相似文献
66.
Claudia Sch?llkopf Karin Ekstr?m Smedby Henrik Hjalgrim Klaus Rostgaard Ole Gadeberg G?ran Roos Anna Porwit-Macdonald Bengt Glimelius Hans-Olov Adami Mads Melbye 《Cancer epidemiology, biomarkers & prevention》2005,14(7):1791-1796
BACKGROUND: Epidemiologic evidence of an association between tobacco smoking and non-Hodgkin's lymphoma has been conflicting. This may reflect that non-Hodgkin's lymphoma comprises several distinct disease entities with different etiologies, as some studies have indicated an association between smoking and follicular lymphoma. OBJECTIVE: To investigate the association between cigarette smoking and non-Hodgkin's lymphoma risk, overall and by subtype. METHODS: As part of a nationwide Danish-Swedish population-based case-control study, we interviewed 3,055 incident non-Hodgkin's lymphoma patients and 3,187 population controls. All lymphomas were uniformly classified according to the WHO classification. We used unconditional logistic regression to estimate adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for the association between cigarette smoking and risk of non-Hodgkin's lymphoma. RESULTS: Cigarette smoking was not associated with the risk of non-Hodgkin's lymphoma overall (OR, 0.97; 95% CI, 0.87-1.08) nor with the major subgroups such as diffuse large B-cell lymphoma (OR, 0.94; 95% CI, 0.79-1.10), chronic lymphocytic leukemia (OR, 0.86; 95% CI, 0.72-1.02), or follicular lymphoma (OR, 1.03; 95% CI, 0.85-1.24). Female smokers were at a marginally increased risk of follicular lymphoma (OR, 1.41; 95% CI, 1.04-1.92). Men who had ever smoked had a significantly increased risk of T-cell lymphoma (OR, 1.67; 95% CI, 1.11-2.51). No dose-response association with cigarette smoking could be established for any lymphoma subgroup. CONCLUSION: We found little evidence of an association between cigarette smoking and non-Hodgkin's lymphoma risk overall. Although increased risks of follicular lymphoma in female smokers and of T-cell lymphoma in male smokers were suggested, no dose-response relationship was observed, leaving limited support for causality. 相似文献
67.
S O Lie J Abrahamsson N Clausen E Forestier H Hasle L Hovi G Jonmundsson L Mellander M A Siimes M Yssing B Zeller G Gustafsson 《Leukemia》2005,19(12):2090-2100
In all, 447 children with acute myeloid leukaemia (AML) have been treated on three consecutive NOPHO studies from July 1984 to December 2001. NOPHO-AML 84 was of moderate intensity with an induction of three courses of cytarabine, 6-thioguanine and doxorubicin followed by four consolidation courses with high-dose cytarabine. The 5-year event-free survival (EFS), disease free survival (DFS) and overall survival (OS) were 29, 37 and 38%. NOPHO-AML 88 was of high intensity with the addition of etoposide and mitoxantrone in selected courses during induction and consolidation. The interval between the induction courses should be as short as possible, that is, time intensity was introduced. The 5-year EFS, DFS and OS were 41, 48 and 46%. In NOPHO-AML 93, the treatment was stratified according to response to first induction course. The protocol utilised the same induction blocks as NOPHO-AML 88, but after the first block, children with a hypoplastic, nonleukaemic bone marrow were allowed to recover before the second block. Consolidation was identical with NOPHO-AML 88. The 5-year EFS, DFS and OS in NOPHO-AML 93 were 48, 52 and 65%. The new NOPHO-AML protocol has been based on experiences from previous protocols with stratification of patients with regard to in vivo response and specific cytogenetic aberrations. 相似文献
68.
69.
70.
Pregnancy complications and subsequent breast cancer risk in the mother: a Nordic population‐based case–control study 下载免费PDF全文
Rebecca Troisi Anne Gulbech Ording Tom Grotmol Ingrid Glimelius Anders Engeland Mika Gissler Britton Trabert Anders Ekbom Laura Madanat‐Harjuoja Henrik Toft Sørensen Steinar Tretli Tone Bjørge 《International journal of cancer. Journal international du cancer》2018,143(8):1904-1913
Certain features of pregnancy are important risk factors for breast cancer, such as protection afforded by young age at first birth. Preeclampsia, a pregnancy complication, is associated with reduced maternal breast cancer risk. However, questions remain regarding causality, biological mechanisms and the relation of other hypertensive conditions to risk. We conducted a population‐based case–control study of breast cancer cases (n = 116,196) in parous women identified through linkage of birth and cancer registries in Denmark, Finland, Norway and Sweden (1967–2013), including up to 10 matched controls per case (n = 1,147,192) sampled from the birth registries (complete data were not available on all variables). Odds ratios (ORs) with 95% confidence intervals (CIs) were derived from unconditional logistic regression models including matching factors (country, maternal birth year) and parity. Hypertension diagnosed before pregnancy (OR 0.87; 95% CI 0.78–0.97), gestational hypertension (OR 0.90; 95% CI 0.86–0.93) and preeclampsia (OR 0.91; 95% CI 0.88–0.95) were associated with reduced breast cancer risk. Results remained similar after adjustment for smoking and maternal body mass index before first pregnancy, and were generally similar stratified by parity, age at breast cancer diagnosis, time since first and last birth, sex of the offspring and calendar time. Except for retained placenta (OR 1.14; 95% CI 0.98–1.32), no other pregnancy complication appeared associated with breast cancer risk. The mechanisms mediating the modest risk reductions for history of preeclampsia or hypertension preceding or arising during pregnancy, and possible increased risk with history of retained placenta are unknown and warrant further laboratory, clinical and epidemiological investigation. 相似文献